Moreover, ADAM10/CX3CL1 serum levels are elevated in rheumatoid arthritis patients and positively predict treatment responsiveness to tocilizumab, a monoclonal antibody targeting the IL-6 receptor37. The gene discussed is CX3CL1; the disease is rheumatoid arthritis.